Skip to main content
Premium Trial:

Request an Annual Quote

Seegene Partners With Spanish Diagnostics Maker to Develop Syndromic qPCR Panels

NEW YORK – Seegene announced today that it has expanded a collaborative partnership with Barcelona, Spain-based diagnostics developer Werfen.

The firms expect to jointly develop syndromic qPCR assays suitable for healthcare systems in Spain and Portugal, Seegene said in a statement, including assays for sexually transmitted infections and drug resistance.

The partnership expands on a current collaboration between Seoul, South Korea-based Seegene and Werfen for the Spanish and Portuguese markets through Seegene's OneSystem business.

One System enables assay development using the firm's syndromic qPCR technologies and digitalized development tools, the firm said, and provides automated manufacturing technologies to produce syndromic assays compatible with Seegene's OneSystem instruments.

The companies are currently discussing the codevelopment of qPCR assays at Werfen's OEM Technology Center in Lliçà d'Amunt, located north of Barcelona. This partnership follows a similar agreement Seegene reached in March with Hylabs in Israel.

Seegene said that it is continuously seeking additional partners from other European countries to join its global network and expects subsequent agreements to be signed throughout this year to accelerate the expansion of its OneSystem business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.